The abstract is read at the publisher; the summary is JClub's.
In Sweden’s acute coronary syndrome PCI population, a default prasugrel policy did not reduce 1-year ischemic events versus a default ticagrelor policy (11.1% vs 11.8%; adjusted OR 0.90).
- Why it matters: It is uncertain which P2Y12 inhibitor should be the preferred default after PCI for acute coronary syndrome, leaving clinicians without clear policy-level guidance.
- What they did: A registry-based, open-label, stepped-wedge, cluster-randomized trial switched seven Swedish regions from ticagrelor to prasugrel across four 9-month periods (2021–2024), with outcomes tracked through national registries.
- The result: Through 1 year, the primary composite endpoint was 11.8% under ticagrelor and 11.1% under prasugrel (adjusted OR 0.90; 95% CI 0.77–1.06), while major bleeding was 4.4% vs 4.2% (adjusted OR 0.80; 95% CI 0.64–0.99).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.